Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who
|
|
- Alannah Gaines
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: (Compound Number SB ) Study Number: TRA Title: A two-part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric patients with previously treated chronic immune (idiopathic) thrombocytopenic purpura (ITP). PETIT2: in PEdiatric patients with Thrombocytopenia from ITP Rationale: The purpose of this Phase III study (TRA115450/PETIT2) was to confirm the efficacy, safety, and tolerability of eltrombopag compared with placebo in pediatric subjects with chronic ITP. Phase: Phase III Study Period: 15-Mar-2012 through 02-Jan-2014 Study Design: This was a two part, double-blind, randomized, placebo-controlled and open-label Phase III study to investigate the efficacy, safety and tolerability of eltrombopag in pediatric subjects with previously treated chronic ITP. In Part 1, the Randomized Period, subjects were randomized 2:1 to receive eltrombopag or placebo in a 13-week double-blind, placebo-controlled treatment period. Subjects were allowed to continue on standard of care. The randomization was stratified by 3 age-defined cohorts: Cohort 1 enrolled subjects between 12 and 17 years old, Cohort 2 enrolled subjects between 6 and 11 years old, and Cohort 3 enrolled subjects between 1 and 5 years old. Subjects who completed treatment in the Randomized Period were eligible to enter Part 2. In Part 2, the -Only Period, subjects received eltrombopag in an open-label manner for 24 weeks. Subjects randomized to placebo in the Randomized Period received up to 24 weeks of eltrombopag treatment, and subjects randomized to eltrombopag in the Randomized Period received up to 37 weeks of eltrombopag treatment. After completion of the -Only Period, subjects were to complete a 24 to 28 week Follow-up Period including an ophthalmic examination 24 weeks after the last dose of study treatment. Centres: This study enrolled subjects at 38 centres in 12 countries: Argentina (1 centre); Czech Republic (4 centres); Germany (3 centres); Hong Kong (1 centre); Israel (5 centres); Italy (4 centres); Russian Federation (4 centres); Spain (3 centres); Taiwan (1 centre); Thailand (5 centres); United Kingdom (5 centres); and United States (2 centres). Indication: Chronic Immune Thrombocytopenia Treatment: Subjects were administered eltrombopag or matching placebo as tablets or powder for oral suspension (PfOS). Subjects between 6 and 17 years of age weighing 27 kg initiated study treatment at 50 mg once daily. Subjects between 6 and 17 years of age weighing <27 kg initiated study treatment at 37.5 mg once daily. The starting dose for East Asian subjects, between 6 and 17 years of age, was 25 mg. For subjects between 1 and 5 years of age, the starting dose was 1.2 mg/kg once daily, or 0.8 mg/kg once daily for East Asian subjects. Throughout the study, the dose of study treatment was titrated for each subject based upon platelet response, to a maximum of 75mg once daily. The dose of study treatment was reduced whenever the platelet count exceeded 200 Gi/L and was interrupted if the platelet count exceeded 400 Gi/L and restarted at the next lower dose. The treatment goal was to have a platelet count in a safe hemostatic range and not to normalize the platelet counts. Objectives: The primary objective of this study was to assess the efficacy of eltrombopag, relative to placebo, in achieving platelet counts of 50 Gi/L, when administered to pediatric subjects with previously treated chronic ITP during the first 12 weeks of Part 1, the Randomized Period. Primary Outcome (Endpoints)/Efficacy : The primary endpoint of the study was the proportion of subjects on eltrombopag, compared to placebo, achieving platelet counts 50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 to 12 of Part 1, the Randomized Period. Secondary Outcome (Endpoints)/Efficacy : Secondary efficacy endpoints for Part 1, the Randomized Period, included the odds of achieving platelet counts 50 Gi/L during the first 12 weeks; proportion of subjects achieving platelet counts 50 Gi/L at any time during the first 12 weeks; proportion of subjects achieving platelet counts 50 Gi/L at any time during the first 6 weeks; weighted mean platelet change (area under the platelet-time curve divided by duration) from baseline to Week 12; maximum period of time with platelet counts continuously 50 Gi/L during the first 12 weeks; proportion of subjects who required protocol-defined rescue treatment; and incidence and severity of symptoms associated with ITP, including bleeding, bruising and petechiae, measured using the WHO Bleeding Scale. Secondary efficacy endpoints for Part 2, the -Only Period, included the proportion of subjects who 1
2 achieved platelet counts 50 Gi/L at any time during Part 2; proportion of weeks in which subjects achieved platelet counts 50 Gi/L, between Weeks 4 to 24 of Part 2; maximum period of time with platelet count continuously 50 Gi/L; proportion of subjects who reduced or discontinued baseline concomitant ITP medications; proportion of subjects who required protocol-defined rescue treatment; and incidence and severity of symptoms associated with ITP, including bleeding, bruising and petechiae, measured using the WHO Bleeding Scale. Safety endpoints included the frequency of adverse events, categorized using Common Terminology Criteria for Adverse Events (CTCAE) v4 toxicity grades, clinical laboratory tests (hematology, chemistry, urinalysis), vital signs (blood pressure and heart rate), and ophthalmic examinations. Pharmacokinetic endpoints: PK data collected in this study were included in a population PK analysis in order to estimate primary model-based PK parameters such as CL/F, Q/F, Vc/F, Vp/F, and ka and the influence of potential covariates on these parameters. Statistical Methods: The primary comparison of interest was the proportion of subjects that received eltrombopag, compared with placebo, who achieved platelet counts 50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 to 12 of Part 1. The primary efficacy analysis was evaluated using stratified Cochran-Mantel-Haenszel (CMH) chi-square test statistics that adjusted for the age cohorts (1 to 5 years, 6 to 11 years and 12 to 17 years). The study was powered to demonstrate a clinically meaningful difference between eltrombopag and placebo with respect to the primary endpoint for the ITT population. A response rate of 10% for placebo and 50% for eltrombopag was assumed based on the response rates at each nominal visit during the first 10 weeks of the placebo-controlled clinical study TRA For the randomized, placebo-controlled part of the study, using a 2:1 randomization, a sample size of 66 evaluable subjects was needed in order to provide at least 90% power at the 5% level of significance (two-sided). Allowing for an additional 10% of subjects to compensate for missing data and drop-outs, approximately 75 subjects (50 eltrombopag; 25 placebo) were planned to be randomized. The intent-to-treat (ITT) population consisted of all randomized subjects and was the primary population used for assessing efficacy. The safety population consisted of all subjects who received at least one dose of the investigational product. Study Population: This study enrolled male or female subjects aged between 1 year and <18 years with a confirmed diagnosis of chronic ITP for at least 1 year and a platelet count <30 Gi/L. Subjects were to be refractory or relapsed after at least one prior ITP therapy or not eligible, for a medical reason, to continue other ITP treatments Number of Subjects: Randomized Period (Part 1) Planned, N Randomised, N Completed Randomized Period, Total Number Subjects Discontinued Study Treatment, 1 (3.4) 2 (3.2) Discontinued Study Treatment due to Adverse Events, 1 (3.4) 2 (3.2) Discontinued Study Treatment due to Lack of Efficacy, 0 0 Discontinued Study Treatment for other reasons, 0 0 Withdrawn due to Lack of Efficacy prior to Part 2, 0 2 (3.2) -Only Period (Part 2) Open-label Received Open-label (Part 2), N (%) 87 (94.6) Completed Part 1 and Part 2, 80 (87.0) Total Number Subjects Discontinued Study Treatment (Part 2), 7 (8.0) Discontinued Study Treatment due to Adverse Events, 4 (4.6) Discontinued Study Treatment due to Lack of Efficacy, 2 (2.3) Discontinued Study Treatment for other reasons, 1 (1.1) Demographics: Randomized Period (Part 1) N (ITT) Females: Males, n 14:15 30:33 Mean Age, years (Range) 9.0 (4-17) 9.0 (1-17) Race, 2
3 African American/African Heritage 0 1 (1.6) Asian 10 (34.5) 21 (33.3) White 19 (65.5) 40 (63.5) Mixed Race 0 1 (1.6) Prior ITP Medication Use 2, 26 (90) 46 (73) Actual Baseline ITP Medication Use, Yes 1 (3.4) 13 (20.6) No 28 (96.6) 50 (79.4) Actual Baseline Platelet Count, 15 Gi/L 19 (65.5) 38 (61.3) a >15 Gi/L 10 (34.5) 24 (38.7) Actual Splenectomy Status, Yes 0 4 (6.3) No 29 (100.0) 59 (93.7) a. One subject did not have a baseline platelet count value on Day 1 Primary Efficacy Results: The proportion of eltrombopag subjects compared with placebo subjects achieving a sustained platelet response in the absence of ITP rescue medication for at least 6 of 8 weeks between Weeks 5 through 12 (Randomized Period) is summarized below: Odds Ratio (E vs P) (95% Confidence Interval) a p-value b Yes 1 (3.4) 25 (39.7) (2.29, ) <0.001 No 28 (96.6) 38 (60.3) a. Adjusted for age cohort and treatment. b. Stratified CMH Chi-square test adjusted for age cohort and treatment. Secondary Outcome Results: Part 1 (Randomized Period) Repeated Measures Analysis of Odds of achieving platelet counts 50 Gi/L during the first 12 weeks (Randomized Period) is summarized below: Statistics Odds-ratio Responders / a % Confidence Interval (8.15, 78.73) a. Generalized linear mixed model with a logit canonical link function adjusted for age cohort and treatment as fixed effects, and subjects and assessments within subjects as random effects. Proportion of subjects that achieved platelet counts 50 Gi/L at any time during the first 12 weeks (Randomized Period) is summarized below: No. of Responders 6 47 Percentage of Responders Odds-ratio Responders / % Confidence Interval (3.99, 34.50) Proportion of subjects that achieved platelet counts 50 Gi/L at any time during the first 6 weeks (Randomized Period) is summarized below: 3
4 No. of Responders 5 39 Percentage of Responders Odds-ratio Responders / % Confidence Interval (2.74, 25.09) Weighted mean platelet counts (area under the platelet-time curve divided by duration) over the first 12 weeks (Randomized Period) is summarized below: Number of Subjects Baseline Mean SD Weighted mean platelet Mean counts SD Model-adjusted platelet Mean counts SE Difference from PLA Mean % Confidence Interval (24.15, 57.88) Maximum continuous duration (weeks) for which a subject continuously maintained a platelet count of 50 Gi/L (Randomized Period) is summarized below: Mean SD th Percentile Median th Percentile Min. 0 0 Max Analysis of subjects who required a protocol-defined rescue treatment (Randomized Period) Logistic Regression Model is summarized below: No. Requiring Rescue Therapy 7 12 Percentage Requiring Rescue Therapy Odds-ratio of Rescue for / % Confidence Interval (0.21, 0.93) The odds of any bleeding (dichotomized WHO Bleeding Scale grades 0 vs 1,2,3,4) during Part 1 is summarized below: Subjects with any bleeding, n(%) 28 (96.6) 51 (81.0) Odds ratio any bleeding / % Confidence Interval a (0.02, 1.25) a. Generalized linear mixed model allowing for baseline dichotomized WHO Bleeding Scale grade, age cohort and treatment as fixed effects. The odds of significant bleeding (dichotomized WHO Bleeding Scale grades 0,1 vs 2,3,4) during Part 1 is summarized below: Subjects with significant bleeding, n(%) 12 (41.4) 21 (33.3) Odds ratio significant bleeding / % Confidence Interval a (0.28, 1.79) a. Generalized linear mixed model allowing for baseline dichotomized WHO Bleeding Scale grade, age cohort and 4
5 treatment as fixed effects. Time to WHO Grade 1 to 4 bleeding data during Randomized Period is summarized below: vs. Hazard Ratio % Confidence Interval (0.70, 1.00) Time to WHO Grade 2 to 4 bleeding data during Randomized Period is summarized below: vs. Hazard Ratio % Confidence Interval (0.76, 1.93) Part 2 (-Only Period) Proportion of subjects that achieved platelet counts 50 Gi/L at any time during -Only Period is summarized below: No. of Responders 70 Percentage of Responders 80.5 Total number of cumulative weeks in which subjects achieved platelet counts 50 Gi/L between weeks 4 to 24 of -Only Period is summarized below: Mean 10.0 SD th Percentile 1.0 Median th Percentile 17.0 Min. 0 Max. a 21 a Maximum potential number of weeks of platelet response was 21 weeks The maximum continuous duration (weeks) for which a subject continuously maintained a platelet count 50 Gi/L for Weeks 1 through 24 (-Only Period) is summarized below: Mean 8.6 SD th Percentile 1.0 Median th Percentile 15.0 Min. 0 Max. 24 Proportion of subjects that had sustained reduction or discontinuation of baseline concomitant ITP medications during -Only Period is summarized below: Subjects with baseline ITP medications, N 15 8 (53.3) Proportion of subjects that required protocol-defined rescue treatment during -Only Period is summarized below: 11 (12.6) PK data analysis was not available at the time of this report, but will be amended to this document when available. Safety Results: The period for collection of AEs and SAEs was from the first dose of study treatment until the 4-week follow-up visit. In addition, any SAEs assessed as related to study participation or treatment, were recorded from the time of subject consent up to and including the 24-week follow-up period. At any time after the 4-week follow-up visit the investigator could report any adverse event that they believed possibly related to study treatment. Post therapy AEs were defined as AEs that started more than 1 day after the last dose of study treatment and up to 30 days after 5
6 the last dose of study treatment were summarized by post-treatment eltrombopag use. All Adverse Events Started On-Therapy : All Cohorts (Randomized Period) Subjects with any AE(s) 21 (72.4) 51 (81.0) Nasopharyngitis 2 (6.9) 11 (17.5) Rhinitis 2 (6.9) 10 (15.9) Epistaxis 6 (20.7) 8 (12.7) Cough 0 7 (11.1) Upper respiratory tract infection 1 (3.4) 7 (11.1) Abdominal pain 0 6 (9.5) Headache 3 (10.3) 6 (9.5) AST increased 0 4 (6.3) Pyrexia 1 (3.4) 4 (6.3) Abdominal pain upper 4 (13.8) 3 (4.8) ALT increased 0 3 (4.8) Decreased appetite 0 3 (4.8) Diarrhea 0 3 (4.8) Oropharyngeal pain 0 3 (4.8) Rash 0 3 (4.8) Toothache 0 3 (4.8) Vitamin D deficiency 0 3 (4.8) Activated partial thromboplastin time prolonged 0 2 (3.2) Blood alkaline phosphatase increased 0 2 (3.2) Blood creatinine increased 1 (3.4) 2 (3.2) Bronchitis 0 2 (3.2) Contusion 0 2 (3.2) Gingival bleeding 1 (3.4) 2 (3.2) Influenza 0 2 (3.2) Mouth haemorrhage 0 2 (3.2) Nausea 0 2 (3.2) Rhinorrhoea 0 2 (3.2) Vomiting 3 (10.3) 2 (3.2) ALT abnormal 0 1 (1.6) Allergy to chemicals 0 1 (1.6) Anemia 0 1 (1.6) AST abnormal 0 1 (1.6) Asthenia 0 1 (1.6) Back pain 0 1 (1.6) Bronchospasm 0 1 (1.6) Bulimia nervosa 0 1 (1.6) Cellulitis 0 1 (1.6) Constipation 0 1 (1.6) Dermatitis allergic 0 1 (1.6) Dyspepsia 0 1 (1.6) Ear pain 1 (3.4) 1 (1.6) Excoriation 0 1 (1.6) Furuncle 0 1 (1.6) Gastritis 1 (3.4) 1 (1.6) Gingivitis 1 (3.4) 1 (1.6) Groin pain 0 1 (1.6) Impetigo 1 (3.4) 1 (1.6) Influenza like illness 1 (3.4) 1 (1.6) Joint injury 0 1 (1.6) 6
7 Lice infestation 0 1 (1.6) Lip haemorrhage 0 1 (1.6) Meningitis aseptic 0 1 (1.6) Menorrhagia 1 (3.4) 1 (1.6) Motion sickness 0 1 (1.6) Non-cardiac chest pain 0 1 (1.6) Osteoporosis 0 1 (1.6) Pain 0 1 (1.6) Paresthesia 0 1 (1.6) Pharyngitis 0 1 (1.6) Platelet count increased 0 1 (1.6) Pneumonia 0 1 (1.6) Pneumonia fungal 0 1 (1.6) Rash pruritic 0 1 (1.6) Retinal vascular disorder 0 1 (1.6) Soft tissue injury 0 1 (1.6) Somnolence 0 1 (1.6) Subcutaneous abscess 0 1 (1.6) Tongue haemorrhage 1 (3.4) 1 (1.6) Tonsillar hypertrophy 0 1 (1.6) Viral pharyngitis 0 1 (1.6) Blood albumin increased 1 (3.4) 0 Ecchymosis 1 (3.4) 0 Eczema 1 (3.4) 0 Gastroenteritis viral 1 (3.4) 0 Haemorrhage 1 (3.4) 0 Helminthic infection 1 (3.4) 0 Hypertensive crisis 1 (3.4) 0 Ingrowing nail 1 (3.4) 0 Leukocytosis 1 (3.4) 0 Limb injury 1 (3.4) 0 Lymphadenitis 1 (3.4) 0 Nasal congestion 1 (3.4) 0 Otosalpingitis 1 (3.4) 0 Papule 1 (3.4) 0 Pericoronitis 1 (3.4) 0 Petechiae 1 (3.4) 0 Respiratory tract infection viral 1 (3.4) 0 Tongue biting 1 (3.4) 0 Urethral haemorrhage 1 (3.4) 0 Wound infection 1 (3.4) 0 Most Common Adverse Events Started On-Therapy (-Only Period) n(%) 7
8 Any event 69 (79.3) Epistaxis 12 (13.8) Upper respiratory tract infection 10 (11.5) Pyrexia 9 (10.3) Cough 8 (9.2) Headache 8 (9.2) Abdominal pain 7 (8.0) AST increased 7 (8.0) Nasopharyngitis 7 (8.0) Pharyngitis 7 (8.0) ALT increased 6 (6.9) Respiratory tract infection 6 (6.9) Vomiting 6 (6.9) Serious Adverse Events: Subjects with non-fatal SAEs (Randomized Period), N (Safety) Subjects with any SAEs 4 (13.8) 5 (7.9) ALT abnormal 0 1 (1.6) AST abnormal 0 1 (1.6) Gingivitis 0 1 (1.6) Influenza 0 1 (1.6) Meningitis aseptic 0 1 (1.6) Pneumonia 0 1 (1.6) Pneumonia fungal 0 1 (1.6) Epistaxis 1 (3.4) 0 Haemorrhage 1 (3.4) 0 Hypertensive crisis 1 (3.4) 0 Petechiae 1 (3.4) 0 Subjects with non-fatal SAEs (Etrombopag-Only Period), Any event 9 (10.3) Epistaxis 2 (2.3) Dengue fever 1 (1.1) Hematoma 1 (1.1) Hematoma infection 1 (1.1) Hemolytic anemia 1 (1.1) Pleural effusion 1 (1.1) Pneumonia 1 (1.1) Rhinitis 1 (1.1) Rhinitis allergic 1 (1.1) Thrombocytopenia 1 (1.1) Upper respiratory tract infection 1 (1.1) Subjects with non-fatal SAEs Post-therapy Randomized Period), (N=1) N=4 Any event 0 1 (25%) Subjects with non-fatal SAEs Post-therapy (-Only Period), N=87 Any event 2 (2.3%) Subjects with non-fatal SAEs Considered to be Related (Randomized Period), Any event 0 1 (1.6) ALT abnormal 0 1 (1.6) AST abnormal 0 1 (1.6) Subjects with non-fatal SAEs Considered to be Related (-Only Period), Any event 1 (1.6) 8
9 Hemolytic anemia 1 (1.6) Subjects with non-fatal SAEs Considered to be Related (Post- Therapy), Any event 0 Subjects with fatal SAEs (Randomized Period), 0 0 Subjects with fatal SAEs (-Only Period), n/a 0 Subjects with fatal SAEs (Post-Therapy)), 0 0 Conclusion: The PETIT2/TRA study demonstrated that treatment with eltrombopag when compared with placebo, resulted in a statistically significant improvements in sustained platelet response in the absence of ITP rescue medication, with 39.7% in the eltrombopag group compared with 3.4% in the placebo group achieving platelet counts 50 Gi/L for 6 of 8 weeks (between Weeks 5 to 12) of the 12-week Randomized Period (p <0.001). During the Randomized Period, the overall incidence of on-therapy AEs was 81.0% in eltrombopag subjects and 72.4% in placebo subjects. The most common AEs ( 10%) in eltrombopag subjects that occurred at a higher incidence compared with placebo subjects were nasopharyngitis, rhinitis, cough, and upper respiratory tract infection. The most common AEs ( 10%) in placebo subjects that occurred at a higher incidence compared with eltrombopag subjects were epistaxis, abdominal pain upper, headache, and vomiting. No deaths occurred at any time during the study. During the Randomized Period, the overall incidence of SAEs was 7.9% in eltrombopag subjects and 13.8% in placebo subjects. 9
UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationExpert Review: Updates in Immune Thrombocytopenia. Reference Slides
Expert Review: Updates in Immune Thrombocytopenia Reference Slides Immune Thrombocytopenia (ITP): Overview ITP causality 1,2 Suboptimal platelet production Dysregulated adaptive immune system Increased
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSubjects from the Safety Population who had GSK PK parameter estimates from any portion of the study. Cohort 1 (N=8)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of safety The analysis was performed on the Total Vaccinated cohort.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Group 1 (Test Group) Group 2 (Reference group):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRevolade Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
April 7, 2016 Revolade Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP Revolade is marketed as Promacta in the United States EU approval of Revolade expands
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)
Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdalimumab M Clinical Study Report Final R&D/14/1263. Page:
Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMenC. MenW MenY
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationD-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdalimumab M Clinical Study Report Final R&D/13/224
Diagnosis and Main Criteria for Inclusion: A parent or guardian had voluntarily signed and dated an informed consent form, approved by an institutional review board/independent ethics committee, after
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Lind M, Polonsky W, Hirsch IB, et al. Effect of continuous glucose monitoring vs conventional therapy on glycemic control among patients type 1 diabetes treated multiple daily
More information